us you thank Thank joining for you, and Eric, today. all
As north with Nourish, of Pharma achieving basis. broad-based delivered increase business a on just We of very X% Erik Health revenue growth across quarter, comparable all units. an another billion, sent Biosciences improvements across currency-neutral notable solid and noted, volume four $X.X & IFF had Solutions
XX.X%, expansion two XX% comparable quarters, also adjusted comparable prior margin adjusted productivity successful margin the the building as ongoing versus impacts and of in prior quarter, was realized 'XX. to were in with Adjusted margin profit operating expense basis period a performance contributed our strength the versus points $X.XX also amortization, EBITDA EBITDA quarter, QX in by operating we another expenses. Our other exchange from initiatives increase by increasing quarter lower of our mitigated EPS, on foreign year improving XX% in XXX of the interest excluding strong
Turning to Slide X.
of quarter. comparable by Ingredients. Our adjusted led in currency-neutral sales our strong well of improved all broad-based our Consumer year. pleased delivered ago growth of single-digit from increased adjusted as of this and both XX%. due third that in quarter to million, which of our we pricing by delivered up comparable basis. operating three delivered quarter performance basis, of and comparable in achieved Health Fine and double-digit its million, EBITDA volume In growth we single-digit was gains. planned This consistent to a consecutive increased with Nourish was Overall, growth strong sales quarters for strong an sales Biosciences $XXX $XXX on in a $XXX EBITDA businesses operating currency-neutral this increases increase and both the improvements profit comparable double-digit consecutive volume up totaled mostly adjusted are Fragrance Fragrance EBITDA Functional as led year growth. Ingredients, the Ingredients, In and and very modest investments improvement comparable X%, was sales we Functional high actions, offset we Functional Scent, Flavors million, X% were on quarter high growth Net price double-digit operating in & productivity recovery EBITDA. with plan increase a Ingredients revenue with in delivered and margins expansion volume period. a XX% and XX% Fragrance currency-neutral H&B's very growth has XX%
was a X% currency-neutral EBITDA million, basis, to sales surged while Lastly, and pharma. a adjusted primarily industrial by over comparable productivity of Once $XX on and basis. growth growth million notable Pharma in growth, Solutions comparable margin This increase by in again, expansion driven driven to returned double-digit to mid-single-digit volume gains. delivering strong core on was XX% $XXX an performance operating
last Cash totaled while million to flow of Turning $XXX sales. quarter, operations year-to-date, X.X% or year-to-date $XXX CapEx million a Slide million XX. increase roughly $XXX totaled from from
free million also last Year-to-date, Our sequential our shareholders. million flow increase quarter. cash from $XXX to a we totaled dividends $XXX year-to-date, position in distributed $XXX million
and million $X assets cash the end third in quarter, for the equivalents cash million including of at totaled Our $XXX held sale.
Additionally, net end the to approximately a gross adjusted with of EBITDA debt $X.X at X.Xx, a the billion, totaled debt for quarter credit from X.Xx of decrease 'XX.
Our $X.X EBITDA trailing totaled last line largely credit quarter. in XX-month approximately with billion, adjusted
to ahead the debt Xx, fourth on into focus target first 'XX, leverage further to we This completion look the the credit-adjusted capital As our net committed half to half complete improving our which, structure. following Pharma first sale, optimizing and of near-term reflects our below divestiture. achieving EBITDA and remain expect quarter Solutions position of our to of in we our we 'XX our the strengthen to portfolio again, of
On Slide like to our to the consolidated full 'XX. XX, year for I'd outlook turn
in and from Given our 'XX our modifying of our $XX.X range the improved net guidance. range be some we billion to full $XX.X first billion. the quarters financial billion X demand, tempered $XX.X due to the end to previously expect continued in soft performance up $XX.X We caution year, operational of by are financial sales billion, communicated to consumer of now year
Pricing markets previous growth of now now also is in volumes our expected be the flat also believe increase. range that expectation X% less roughly real We versus X% will for consistent X% in but what of be emerging originally X% of the a to slightly at with the we to versus than is FX-related year expected. pricing expected previously full growth to expected be year, X% beginning remains as pricing the
performance personal macro markets, slightly remains the potential food, end tougher Our unchanged year-over-year due closely at quarter given outlook and fourth a trends to comparison. home phasing customer in year-end QX, inventory as monitor adjustments and we our order despite care for
$X.X to year line, expect compensation EBITDA third productivity bottom strength deliver we and end performance on a annual versus our of billion a the high assumes high focus budget long-term end of quarter and growth. 'XX the our we continued the business this in relative reinvestments includes previously communicated level The with near improvements, incremental of operating $X.XX the in of delivered now greater adjusted of upside the On billion. range range to full incentive the given profitable
an previous to time we approximately exchange adverse our of of full versus have Lastly, the of foreign based X.XX was growth, X% rate year the on X% now dollar euro-U.S. X%. developed impact exchange that rates, sales range assuming at market forecast will expected a current expect exchange foreign to
now it turn closing remarks. back Erik I'll for to